This list contains references from the content that can be linked to their source. For a full set of references and notes please see the PDF or HTML where available.
C. W. Berridge and B. D. Waterhouse (2003). The locus coeruleus-noradrenergic system: modulation of behavioral state and state-dependent cognitive processes. Brain Research Brain Research Review, 42, 33–84.
W. Bondareff , C. Q. Mountjoy and M. Roth (1982). Loss of neurons of origin of the adrenergic projection to cerebral cortex (nucleus locus ceruleus) in senile dementia. Neurology, 32, 164–168.
V. Chan-Palay and E. Asan (1989). Alterations in catecholamine neurons of the locus coeruleus in senile dementia of the Alzheimer's type and in Parkinson's disease with and without dementia and depression. Journal of Comparative Neurology, 287, 373–392.
P. P. De Deyn et al. (2004). Olanzapine versus placebo in the treatment of psychosis with or without associated behavioral disturbances in patients with Alzheimer's disease. International Journal of Geriatric Psychiatry, 19, 115–126.
P. De Deyn et al. (2005). Aripiprazole for the treatment of psychosis in patients with Alzheimer's disease: a randomized, placebo-controlled study. Journal of Clinical Psychopharmacoly, 25, 463–467.
D. P. Devanand et al. (2012). Relapse risk after discontinuation of risperidone in Alzheimer's disease. New England Journal of Medicine, 367, 1497–1507.
S. I. Finkel et al. (1995). A randomized, placebo-controlled trial of thiothixene in agitated, demented nursing home patients. International Journal of Geriatric Psychiatry, 10, 129–136.
P. Kamble , H. Chen , J. T. Sherer and R. R. Aparasu (2009). Use of antipsychotics among elderly nursing home residents with dementia in the US: an analysis of National Survey Data. Drugs & Aging, 26, 483–492.
I. Katz , P. P. de Deyn , J. Mintzer , A. Greenspan , Y. Zhu and H. Brodaty (2007). The efficacy and safety of risperidone in the treatment of psychosis of Alzheimer's disease and mixed dementia: a meta-analysis of 4 placebo-controlled clinical trials. International Journal of Geriatric Psychiatry, 22, 475–484.
I. R. Katz , D. V. Jeste , J. E. Mintzer , C. Clyde , J. Napolitano and M. Brecher (1999). Comparison of risperidone and placebo for psychosis and behavioral disturbances associated with dementia: a randomized, double-blind trial. Risperidone Study Group. Journal of Clinical Psychiatry, 60, 107–115.
O. L. Lopez et al. (2013). The long-term effects of conventional and atypical antipsychotics in patients with probable Alzheimer's disease. American Journal of Psychiatry, 170, 1051–1058.
C. G. Lyketsos et al. (2006). Position statement of the American Association for Geriatric Psychiatry regarding principles of care for patients with dementia resulting from Alzheimer's disease. American Journal of Geriatric Psychiatry, 14, 561–572.
J. Mintzer et al. (2006). Risperidone in the treatment of psychosis of Alzheimer's disease: results from a prospective clinical trial. American Journal of Geriatric Psychiatry, 14, 280–291.
J. E. Mintzer et al. (2007). Aripiprazole for the treatment of psychoses in institutionalized patients with Alzheimer's dementia: a multicenter, randomized, double-blind, placebo-controlled assessment of three fixed doses. American Journal of Geriatric Psychiatry, 15, 918–931.
H. A. Nasrallah (2008). Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Molecular Psychiatry, 13, 27–35.
E. J. Nestler , A. McMahon , E. L. Sabban , J. F. Tallman and R. S. Duman (1990). Chronic antidepressant administration decreases the expression of tyrosine hydroxylase in the rat locus coeruleus. Proceedings of the National Academy of Sciences USA, 87, 7522–7526.
A. L. Nyth and C. G. Gottfries (1990). The clinical efficacy of citalopram in treatment of emotional disturbances in dementia disorders. A Nordic multicentre study. British Journal of Psychiatry, 157, 894–901.
E. R. Peskind et al. (1995). Effects of Alzheimer's disease and normal aging on cerebrospinal fluid norepinephrine responses to yohimbine and clonidine. Archives of General Psychiatry, 52, 774–782.
E. R. Peskind et al. (2005). Propranolol for disruptive behaviors in nursing home residents with probable or possible Alzheimer's disease: a placebo-controlled study. Alzheimer Disease & Associated Disorders, 19, 23–28.
B. G. Pollock et al. (2002). Comparison of citalopram, perphenazine, and placebo for the acute treatment of psychosis and behavioral disturbances in hospitalized, demented patients. American Journal of Psychiatry, 159, 460–465.
A. P. Porsteinsson et al. (2014). Effect of citalopram on agitation in Alzheimer's disease: the cited randomized clinical trial. JAMA, 311, 682–691.
M. M. Raivio , J. V. Laurila , T. E. Strandberg , R. S. Tilvis and K. H. Pitkala (2007). Neither atypical nor conventional antipsychotics increase mortality or hospital admissions among elderly patients with dementia: a two-year prospective study. American Journal of Geriatric Psychiatry, 15, 416–424.
B. P. Ramos and A. F. Arnsten (2007). Adrenergic pharmacology and cognition: focus on the prefrontal cortex. Pharmacology & Therapeutics, 113, 523–536.
M. A. Raskind , E. R. Peskind , J. B. Halter and D. C. Jimerson (1984). Norepinephrine and MHPG levels in CSF and plasma in Alzheimer's disease. Arcives of General Psychiatry, 41, 343–346.
M. A. Raskind et al. (2007). A parallel group placebo controlled study of prazosin for trauma nightmares and sleep disturbance in combat veterans with post-traumatic stress disorder. Biological Psychiatry, 61, 928–934.
M. A. Raskind et al. (2013). A trial of prazosin for combat trauma PTSD with nightmares in active-duty soldiers returned from Iraq and Afghanistan. American Journal of Psychiatry, 170, 1003–1010.
B. L. Roth , D. J. Sheffler and W. K. Kroeze (2004). Magic shotguns versus magic bullets: selectively non-selective drugs for mood disorders and schizophrenia. Nature Reviews Drug Discovery, 3, 353–359.
A. Russo-Neustadt , T. J. Zomorodian and C. W. Cotman (1998). Preserved cerebellar tyrosine hydroxylase-immunoreactive neuronal fibers in a behaviorally aggressive subgroup of Alzheimer's disease patients. Neuroscience, 87, 55–61.
L. S. Schneider , K. S. Dagerman and P. Insel (2005). Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials. JAMA, 294, 1934–1943.
L. Simoni-Wastila , P. T. Ryder , J. Qian , I. H. Zuckerman , T. Shaffer and L. Zhao (2009). Association of antipsychotic use with hospital events and mortality among medicare beneficiaries residing in long-term care facilities. American Journal of Geriatric Psychiatry, 17, 417–427.
J. S. Street et al. (2000). Olanzapine treatment of psychotic and behavioral symptoms in patients with Alzheimer's disease in nursing care facilities: a double-blind, randomized, placebo-controlled trial. The HGEU Study Group. Archives of General Psychiatry, 57, 968–976.
J. E. Streim et al. (2008). A randomized, double-blind, placebo-controlled study of aripiprazole for the treatment of psychosis in nursing home patients with Alzheimer's disease. American Journal of Geriatric Psychiatry, 16, 537–550.
P. Szot , S. S. White , J. L. Greenup , J. B. Leverenz , E. R. Peskind and M. A. Raskind (2006). Compensatory changes in the noradrenergic nervous system in the locus ceruleus and hippocampus of postmortem subjects with Alzheimer's disease and dementia with Lewy bodies. Journal of Neuroscience, 26, 467–478.
P. Szot , S. S. White , J. L. Greenup , J. B. Leverenz , E. R. Peskind and M. A. Raskind (2007). Changes in adrenoreceptors in the prefrontal cortex of subjects with dementia: evidence of compensatory changes. Neuroscience, 146, 471–480.
P. N. Tariot et al. (2006). Quetiapine treatment of psychosis associated with dementia: a double-blind, randomized, placebo-controlled clinical trial. American Journal of Geriatric Psychiatry, 14, 767–776.
B. E. Tomlinson , D. Irving and G. Blessed (1981). Cell loss in the locus coeruleus in senile dementia of Alzheimer type. Journal of the Neurological Sciences, 49, 419–428.
L. Y. Wang et al. (2009). Prazosin for the treatment of behavioral symptoms in patients with Alzheimer's disease with agitation and aggression. American Journal of Geriatric Psychiatry, 17, 744–751.
C. H. West , J. C. Ritchie , K. A. Boss-Williams and J. M. Weiss (2009). Antidepressant drugs with differing pharmacological actions decrease activity of locus coeruleus neurons. International Journal of Neuropsychopharmacology, 12, 627–641.
K. X. Zhong , P. N. Tariot , J. Mintzer , M. C. Minkwitz and N. A. Devine (2007). Quetiapine to treat agitation in dementia: a randomized, double-blind, placebo-controlled study. Current Alzheimer Research, 4, 81–93.